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The Epstein-Barr virus (EBV) BGLF4 gene encodes a serine/threonine protein kinase (PK) that is expressed
in the cytolytic cycle. EBV nuclear antigen 2 (EBNA2) is a key latency gene essential for immortalization of B
lymphocytes and transactivation of viral and cellular promoters. Here we report that EBV PK phosphorylates
EBNA2 at Ser-243 and that these two proteins physically associate. PK suppresses EBNA2’s ability to
transactivate the LMP1 promoter, and Ser-243 of EBNA2 is involved in this suppression. Moreover, EBNA2
is hyperphosphorylated during EBV reactivation in latently infected B cells, which is associated with decreased
LMP1 protein levels. This is the first report about the effect of EBV PK on the function of one of its target
proteins and regulation of EBNA2 phosphorylation during the EBV lytic cycle.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
with tropism for B cells and epithelial cells that establishes a
lifelong persistent infection in more than 90% of the world’s
population. EBV produces both latent and lytic forms of in-
fection. During latent infection, only a limited set of EBV
genes is expressed. Among them, the Epstein-Barr nuclear
antigen 2 (EBNA2) is a key latency gene; it regulates tran-
scription of viral and cellular genes and is essential for immor-
talization of B lymphocytes (5, 14, 44). A principal target of
EBNA2 is the EBV latent membrane protein 1 (LMP1) (1, 45),
an oncoprotein whose expression is also essential for immor-
talization of B lymphocytes (22).
In most asymptomatic carriers of EBV, the virus periodically
converts to the cytolytic form of infection, in which the full
repertoire of viral genes is expressed. The EBV protein kinase
(PK) encoded by the EBV BGLF4 gene is one of the lytic cycle
gene products; it shows early kinetics during viral reactivation
in latently infected Akata cells (11). EBV PK belongs to the
group of herpesvirus-encoded protein kinases exemplified by
UL13 of herpes simplex virus type 1, which is conserved in all
herpesviruses (3, 30, 41). It has been identified as a Ser/Thr
protein kinase by use of amino-acid-sequence alignment of
regions conserved within the catalytic domains of protein ki-
nases (3, 41) and is the only potential protein kinase identified
in the EBV genome. The protein phosphorylates a number of
viral and cellular proteins, including the EBV BMRF1 gene
product (EA-D), the DNA polymerase processivity factor (4,
11); EBV nuclear antigen leader protein (EBNA-LP) (19), an
EBV latency gene, which cotransactivates EBNA2-responsive
promoters in an EBNA2-dependent manner (15, 33); PK itself
(4, 9, 18); and the cellular translation-elongation factor 1 delta
(EF-1) (18, 21). Most interestingly, EBV PK phosphorylates
EBNA-LP (19) and EF-1 (21) at the same sites as cdc2 kinase.
In general, viral protein kinases of the UL13 group tend to
target the same sites on the substrate as cdc2 (19–21). Al-
though EBV PK phosphorylates important viral and cellular
proteins, to date there is no evidence showing whether this
phosphorylation influences functions of its target proteins.
EBNA2 is a phosphoprotein (12, 13); its phosphorylation by
casein kinase II is important for growth transformation (24);
however, whether constitutive phosphorylation of EBNA2 in-
fluences its transactivation function is unknown. We have dis-
covered that phosphorylation of EBNA2 in latent infection is
regulated during the cell cycle, with the protein being specifi-
cally hyperphosphorylated in mitosis. The result is that tran-
scriptional activity of the hyperphosphorylated protein is sup-
pressed (47). cdc2 kinase, the key regulator of mitosis (8, 28),
is involved in hyperphosphorylation of EBNA2 in latently in-
fected cells (47). Since EBV PK mimics cdc2 kinase in phos-
phorylating EBNA-LP and EF-1 (19, 21), in this study we
examine whether EBV PK, a viral lytic cycle protein, also
phosphorylates EBNA2 and how this phosphorylation affects
EBNA2 function.
EBV PK phosphorylates EBNA2 at Ser-243. First, we stud-
ied whether EBNA2 is hyperphosphorylated when coexpressed
with EBV PK. pSG5 EBNA2 (a gift from P. D. Ling) was
transfected alone or cotransfected with pcDNA3-BGLF4-
FLAG (29) into HeLa cells with the use of FuGENE6
(Roche), followed by immunoblotting with EBNA2 antibody
(PE2, DAKO) as described previously (47). Migration of
EBNA2 was retarded when cotransfected with PK (Fig. 1 A,
left panel). To confirm that the shift in migration is due to
phosphorylation, EBNA2 was immunoprecipitated with
EBNA2 antibody from the cell lysates and treated with -phos-
phatase (-PPase)(NEB) at 30°C for 1 h as described before
(47). As shown in Fig. 1A, right panel, -PPase treatment
shifted both hypo- and hyperphosphorylated EBNA2 to its
unphosphorylated form. The results indicate, therefore, that
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EBNA2 is hyperphosphorylated in vivo when coexpressed with
EBV PK in HeLa cells.
Second, we studied whether EBV PK can directly phosphor-
ylate EBNA2 and which site is involved in this phosphoryla-
tion. Since EBV PK phosphorylates the same motif as cdc2
kinase in EBNA-LP (19) and EF-1 (21), and Ser-243 of
EBNA2 is a putative site of phosphorylation by cdc2, we tested
whether EBV PK can directly phosphorylate EBNA2 at Ser-
243 in vitro. An EBNA2 fragment encoding amino acids (aa)
185 to 315 (EBNA2 185-315aa) or aa 185 to 315 S243A
(EBNA2 185-315aa S243A), in which Ser-243 was substituted
with alanine, was expressed as a fusion protein with glutathi-
one S-transferase (GST) in bacteria and purified by standard
techniques (38). Purified protein was of the expected size, and
its expression was confirmed by immunoblotting with GST
antibody (data not shown). The BGLF4 gene or the K102I
mutant of BGLF4, which has lost its kinase activity due to
mutation of the invariant catalytic lysine, was cloned into bac-
ulovirus genomes as a fusion with GST and His6 tags (18, 19)
(the viruses were a gift from Y. Kawaguchi) and expressed in
insect cells following standard protocols (34). The protein pu-
rification and in vitro kinase assay protocols were described
previously (18, 19). Purified GST-EBNA2 185-315aa, GST-
EBNA2 185-315aa S243A, or GST (1 g each) was incu-
bated in the kinase assays for 30 min at 37°C with purified PK
or PK K102I as a negative control. The reaction mixtures were
separated on sodium dodecyl sulfate (SDS)-polyacrylamide
gels, and after staining with Coomassie bright blue (CBB)
(Sigma), the gels were analyzed with a PhosphorImager (Mo-
lecular Dynamics). The results show that the GST-EBNA2
FIG. 1. EBV PK phosphorylates EBNA2 at Ser-243. (A) Hyperphosphorylation of EBNA2 when coexpressed with EBV PK in vivo. HeLa cells
were transfected with pSG5-EBNA2 alone or cotransfected with pcDNA-BGLF4-FLAG and collected 48 h after transfection. Left panel,
immunoblotting for EBNA2; right panel, EBNA2 immunoprecipitated with EBNA2 antibody from the cell lysates was subjected to immunoblot-
ting directly () or after treatment with 2,000 units of -PPase (). (B) In vitro kinase assay. Phosphorylation of purified GST-EBNA2 185-315aa
(GST E2) or GST-EBNA2 185-315aa S243A (GST E2 S243A) by EBV PK (PK) or kinase-dead PK (mt PK) was carried out. The whole reaction
mixtures were separated by SDS-polyacrylamide gel electrophoresis (4 to 20% gradient gels); after CBB staining, gels were exposed on a
PhosphorImager. (C) Involvement of Ser-243 in phosphorylation of EBNA2 by PK in vivo. pSG5-EBNA2 wild type or the S243A mutant of
EBNA2 was coexpressed with EBV PK or empty vector in HeLa cells. Whole-cell lysates were subjected to immunoprecipitation with EBNA2
antibody, washed extensively, blotted, and probed with mouse monoclonal phosphoserine antibody or EBNA2 antibody.
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185-315aa fusion protein was phosphorylated by EBV PK,
whereas GST-EBNA2 S243A was not (Fig. 1B). Autophos-
phorylation was selected as a measure of kinase activity. As
expected, the kinase-dead mutant PK K102I phosphorylated
neither itself nor EBNA2 (Fig. 1B). Purified GST was not
phosphorylated by either PK or the kinase-dead mutant PK
K102I, as published previously (19) (data not shown). CBB
staining shows that essentially equal amounts of either protein
were used in each kinase assay. Therefore, the results demon-
strate that PK directly phosphorylates EBNA2 at Ser-243 in
vitro.
Third, we studied whether Ser-243 of EBNA2 is involved in
PK phosphorylation of EBNA2 in vivo. pSG5 EBNA2 or pSG5
EBNA2 S243A was cotransfected with pcDNA3-BGLF4-
FLAG (29) into HeLa cells. Cell lysates were immunoprecipi-
tated with EBNA2 antibody, and the immunocomplex was
probed with mouse monoclonal phosphoserine antibody
(Sigma, P-3430) or EBNA2 antibody as described before (24).
As shown in Fig. 1C, substitution of serine at Ser-243 resulted
in a clear decrease in overall EBNA2 serine phosphorylation
when coexpressed with PK (left panel) but not with empty
vector (right panel). Immunoblotting of EBNA2 shows essen-
tially the same amount of EBNA2 in each lane (Fig. 1C). The
results indicate that Ser-243 of EBNA2 is involved in hyper-
phosphorylation of EBNA2 when coexpressed with EBV PK in
vivo.
Association of EBV PK with EBNA2. EBNA2 is a nuclear
protein (35, 39). Recently we have demonstrated the nuclear
localization of EBV PK (10). Thus, next we explored whether
PK and EBNA2 can physically associate. HeLa cells were
transfected with either pSG5-EBNA2 or pcDNA-BGLF4-
FLAG (29) or both. Transfection with pcDNA3 served as a
negative control. Aliquots of cell lysates from each transfection
were subjected to immunoprecipitation with EBNA2 and
FLAG (M2) antibodies or with normal mouse immunoglobulin
G as a negative control, and immunocomplexes were probed
with EBNA2 or FLAG antibodies. As shown in Fig. 2, lane 2,
EBNA2 can be coimmunoprecipitated with PK. We consis-
tently detected less EBNA2 coimmunoprecipitated with PK
compared with the amount precipitated with EBNA2 antibody.
PK could not be immunoprecipitated with the EBNA2 anti-
body (Fig. 2, lane 1), perhaps because the binding site is
masked by the EBNA2 antibody; a similar situation was en-
countered in attempts to coimmunoprecipitate cdc2 kinase
with EBNA2 antibody (6, 7, 47). The results indicate that
EBNA2 and EBV PK physically associate.
EBV PK suppresses EBNA2 transactivation of the LMP1
promoter. EBNA2 is a key transactivator of a number of viral
and cellular gene promoters, including the promoter for
LMP1, the principal EBV oncoprotein. Using the LMP1 pro-
moter as a prototype, first we studied whether EBV PK can
influence its transactivation by EBNA2. The LMP-1 promoter
construct pGL2 (512/72)-luciferase (a gift from E. Kieff)
was cotransfected with pSG5-EBNA2, pHD/BGLF4, or pHD/
K128Q (11) in different combinations into DG75, an EBV-
negative BL cell line, as described before (47). The K128Q
mutation in pHD/K128Q corresponds to the K102I mutation
in EBV PK expressed in insect cells (18, 19). In both muta-
tions, the invariant lysine 102 is changed in order to destroy
kinase activity. The pRL-TK plasmid (Promega), which con-
tains the Renilla luciferase gene, was cotransfected as an inter-
nal standard. Cells were collected 48 h after transfection, and
cell lysates were prepared according to Promega’s protocol.
Luciferase activity was measured with a luminometer (Pro-
mega) and normalized against the activity of the Renilla lucif-
erase gene. As shown in Fig. 3A, neither PK nor kinase-dead
PK alone activates LMP1 promoter activity. However, EBV
PK suppresses EBNA2’s ability to transactivate the LMP1 pro-
moter (P  0.01), whereas the kinase-dead PK has no such
effect. Immunoblotting revealed that EBNA2 became hyper-
phosphorylated when coexpressed with PK but not with kinase-
dead PK (Fig. 3A). The results indicate, therefore, that EBV
PK suppresses EBNA2 function and that the kinase activity of
PK is involved in this effect. Second, we studied whether Ser-
243 of EBNA2, is involved in suppression of EBNA2 transac-
tivation by PK. Similar promoter-reporter assays were carried
FIG. 2. Coimmunoprecipitation of EBNA2 and EBV PK. HeLa cells were transfected with pSG5-EBNA2 (EBNA2) (lanes 7, 8, 9) or
pcDNA-BGLF4-FLAG (PK) alone (lanes 4, 5, 6) or cotransfected with both plasmids (EBNA2PK) (lanes 1, 2, 3). Transfection with pcDNA3
served as a negative control (lanes 10, 11, 12). Cells were collected 48 h posttransfection, and aliquots of cell lysates from each transfection were
subjected to immunoprecipitation with antibodies against EBNA2 or FLAG; normal mouse immunoglobulin G was used as a negative control.
Immunocomplexes were resolved in 10% SDS-polyacrylamide gel electrophoresis, and immunoblots were carried out for EBNA2 and FLAG from
the same gel. Whole-cell lysates before immunoprecipitation served as an input control (lanes 13, 14, 15, 16), and -actin was used as a loading
control.
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out as described above to compare transactivation of pLMP1
by EBNA2 and EBNA2 S243A in the absence or presence of
EBV PK. As shown in Fig. 3B, there is no significant difference
between transactivation of the LMP1 promoter by EBNA2 and
EBNA2 S243A in the absence of PK. However, in the presence
of PK, substitution of Ser-243 with alanine (EBNA2 S243A)
partly restored EBNA2 transactivation of pLMP1 that is sup-
pressed by PK (P  0.01). Also, the phosphomimetic mutation
of EBNA2 Ser-243 to glutamic acid or aspartic acid (24–26, 37,
46) resulted in suppressed induction of endogenous LMP1
expression in transfected P3HR1 cells (unpublished results).
Thus, these data suggest that Ser-243 of EBNA2 is involved at
least partly in suppression of its transactivation of pLMP1 by
PK, although there might be other functionally important EBV
PK phosphorylation sites in EBNA2.
Hyperphosphorylation of EBNA2 and decreased LMP1 pro-
tein levels during EBV reactivation in type III latency. EBNA2
is a latent gene product, whereas EBV PK is expressed and
active in the viral lytic cycle. Since EBNA2 is hyperphosphor-
ylated when coexpressed with PK and hyperphosphorylation of
EBNA2 by PK suppresses its transactivation of pLMP1, next
we studied whether EBNA2 is hyperphosphorylated and the
LMP1 protein level is decreased during EBV reactivation in
type III latency cells. A tetracycline-inducible system for ex-
pression of the BZLF1 protein in B95-8 (LCL) cells was used
for this purpose as described previously, since expression of
BZLF1 drives EBV reactivation and the lytic cycle in latently
infected cells (23). As shown in Fig. 4, after induction of cells
with doxycycline, migration of EBNA2 is retarded compared
with that in noninduced cells. A  PPase assay confirmed that
the shift in EBNA2 migration was caused by hyperphosphory-
lation of EBNA2 similar to that shown in Fig. 1A, right panel
(data not shown). Hyperphosphorylation of the EBV BMRF1
gene product (EA-D), which is a substrate of EBV PK (4, 11),
was detected by immunoblotting with EA-D antibody (Capri-
corn Products) and used to confirm the induction of the lytic
cycle and PK activity. The data indicate that EBNA2 is hyper-
phosphorylated during EBV reactivation when EBV PK is
active. As shown in Fig. 4, the endogenous LMP1 protein level
is decreased after the induction of the lytic cycle. Doxycycline
by itself has no effect on either EBNA2 phosphorylation or
LMP1 expression in B95-8 cells (data not shown). The results
show in vivo the correlation between hyperphosphorylation of
EBNA2 and decreased LMP1 protein levels upon cytolytic
induction of latently infected cells.
Several UL13 homologs of herpesvirus-encoded protein ki-
nases target the same substrates and even the same phosphor-
FIG. 3. Phosphorylation of EBNA2 by EBV PK suppresses transactivation of the LMP1 promoter. (A) LMP-1 promoter construct pGL2
(512/72)-luciferase was cotransfected with pSG5 EBNA2 (EBNA2), pHD/BGLF4 (PK), or pHD/K128Q (PK K128Q) in different combina-
tions; pRL-TK plasmid was cotransfected as an internal standard. Levels of transactivation of the LMP-1 promoter are normalized to the vector
control. Each data point represents the average of three independent experiments, each done in triplicate. Error bars represent the means 	
standard errors. Immunoblotting shows the EBNA2 expression level in each transfection; -actin was used as a loading control. (B) The EBNA2
S243A mutant was tested similarly as detailed in panel A.
FIG. 4. Hyperphosphorylation of EBNA2 and decreased LMP1
protein level during EBV reactivation. The tetracycline-inducible cell
line B95-8 BZLF1 was induced with doxycycline at a final concentra-
tion of 1 g/ml for 72 h, and immunoblots of EBNA2, LMP1, and
EA-D were carried out in induced (Id) and noninduced (N-Id) cells.
-Actin served as a loading control.
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ylation sites as cdc2 kinase (19, 21). Phosphorylation of
EBNA2 by EBV PK and cdc2 kinase (47) provides additional
evidence of targeting the same substrate by a herpesvirus-
encoded protein kinase and cdc2. A number of viral and cel-
lular gene products were reported to be phosphorylated by
EBV PK (4, 11, 18, 19, 21); however, none of these reports
demonstrated the effect of the EBV PK on functions of its
target proteins. To the best of our knowledge, this is the first
report that demonstrates such an effect. Based on the present
results and our report that hyperphosphorylation of EBNA2 in
mitosis suppresses its function (47), it is tempting to predict
that EBV PK and cdc2 kinase have similar effects on EBNA2
function and phosphorylate the same sites on EBNA2.
EBNA2, the key EBV latency gene, has been known to be a
phosphoprotein for more than a decade, but only recently has
it been shown that EBNA2 function is regulated by phosphor-
ylation in latently infected cells (24, 47). The evidence pre-
sented here is the first indication of possible regulation of
EBNA2 function through phosphorylation during the EBV
lytic cycle.
LMP1 is generally viewed as a latency protein. Regulation of
the LMP1 promoter has been extensively studied in EBV la-
tency (15, 16, 32, 45); however, whether and how the LMP1
promoter is regulated during the lytic cycle are unknown. Re-
cently a possible role for LMP1 in the lytic cycle has emerged.
It has been reported that LMP1 inhibits induction and pro-
gression of the EBV lytic cycle (2, 36), the benefit of which in
vivo could be that cytotoxicity of this viral product for the host
is limited and, at any given time, viral antigen release may be
below a threshold for antigen presentation and an efficient
immune response. Thus, regulation of LMP1 promoter activity
during the lytic cycle is of considerable potential interest. Sup-
pression of LMP1 promoter activity in response to hyperphos-
phorylation of EBNA2 by PK and decreased endogenous
LMP1 protein levels in lyticly induced type III latency cells
suggest that the LMP1 promoter may be down-regulated dur-
ing the lytic cycle. Thus, hyperphosphorylation of EBNA2 by
PK might contribute to the promotion of lytic cycle progression
by inhibiting LMP1 expression and providing a more precise
level of regulation as the lytic cycle ultimately progresses.
Besides pLMP1, EBNA2 upregulates all the other latency
gene promoters, including Cp (27, 43), which drives the tran-
scription of all the EBNAs; it also upregulates pLMP2A (31)
as well as a number of key cellular genes (17, 27, 40, 42). It is
reasonable to predict that other EBNA2-responsive promoters
may also be similarly influenced by EBV PK through phos-
phorylation of EBNA2. Thus, although the significance of PK-
induced suppression of EBNA2 functions in the cytolytic cycle
is yet to be established, it may shed light on an area of EBV
biology that is largely unexplored.
We thank Jeffery Lin and E. Kieff for pGL2 (512/72) and
LMP1p-Luc plasmids and Paul D. Ling for the pSG5 EBNA2 plasmid,
Y. Kawaguchi for providing the EBV BGLF4 and the BGLF4 K102I
mutant expressing recombinant baculoviruses, M. Marschall for the
pcDNA-BGLF4-FLAG plasmid, T. Tsurumi for the BZLF1 tetracy-
cline-inducible stable cell line B95-8, and Shannon Kenney, Julia
Shackelford, and Matthew G. Davenport for valuable discussion of the
data.
This work was supported in part by grants from the National Cancer
Institute (CA 19014) and from the National Institutes of Health (HL
64851).
REFERENCES
1. Abbot, S. D., M. Rowe, K. Cadwallader, A. Ricksten, J. Gordon, F. Wang, L.
Rymo, and A. B. Rickinson. 1990. Epstein-Barr virus nuclear antigen 2
induces expression of the virus-encoded latent membrane protein. J. Virol.
64:2126–2134.
2. Adler, B., E. Schaadt, B. Kempkes, U. Zimber-Strobl, B. Baier, and G. W.
Bornkamm. 2002. Control of Epstein-Barr virus reactivation by activated
CD40 and viral latent membrane protein 1. Proc. Natl. Acad. Sci. USA
99:437–442.
3. Chee, M., G. Lawrence, and B. Barrell. 1989. Alpha-, beta- and gammaher-
pesviruses encode a putative phosphotransferase. J. Gen. Virol. 70:1151–
1160.
4. Chen, M. R., S. J. Chang, H. Huang, and J. Y. Chen. 2000. A protein kinase
activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral
early antigen EA-D in vitro. J. Virol. 74:3093–3104.
5. Cohen, J. I., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus
nuclear protein 2 is a key determinant of lymphocyte transformation. Proc.
Natl. Acad. Sci. USA 86:9558–9562.
6. Dillner, J., B. Kallin, G. Klein, H. Jornvall, H. Alexander, and R. Lerner.
1985. Antibodies against synthetic peptides react with the second Epstein-
Barr virus-associated nuclear antigen. EMBO J. 4:1813–1818.
7. Dillner, J., V. Wendel-Hansen, G. Kjellstrom, B. Kallin, and A. Rosen. 1988.
Purification and characterization of the Epstein-Barr virus nuclear antigen 2
using monoclonal antipeptide antibody. Int. J. Cancer 42:721–727.
8. Furukawa, Y., S. Iwase, Y. Terui, J. Kikuchi, T. Sakai, M. Nakamura, S.
Kitagawa, and M. Kitagawa. 1996. Transcriptional activation of the cdc2
gene is associated with Fas-induced apoptosis of human hematopoietic cells.
J. Biol. Chem. 271:28469–28477.
9. Gershburg, E., K. Hong, and J. S. Pagano. 2004. Effects of maribavir and
selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and
on viral lytic replication. Antimicrob. Agents Chemother. 48:1900–1903.
10. Gershburg, E., M. Marschall, K. Hong, and J. S. Pagano. 2004. Expression
and localization of the Epstein-Barr virus-encoded protein kinase. J. Virol.
78:12140–12146.
11. Gershburg, E., and J. S. Pagano. 2002. Phosphorylation of the Epstein-Barr
virus (EBV) DNA polymerase processivity factor EA-D by the EBV-en-
coded protein kinase and effects of the L-riboside benzimidazole 1263W94.
J. Virol. 76:998–1003.
12. Grasser, F. A., S. Gottel, P. Haiss, B. Boldyreff, O. G. Issinger, and N.
Mueller-Lantzsch. 1992. Phosphorylation of the Epstein-Barr virus nuclear
antigen 2. J. Virol. 186:1694–1710.
13. Grasser, F. A., P. Haiss, and N. Mueller-Lantzsch. 1991. Biochemical char-
acterization of Epstein-Barr virus nuclear antigen 2A. J. Virol. 65:3779–3788.
14. Hammerschmidt, W., and B. Sugden. 1989. Genetic analysis of immortaliz-
ing functions of Epstein-Barr virus in human B lymphocytes. Nature 340:
393–397.
15. Harada, S., and E. Kieff. 1997. Epstein-Barr virus nuclear protein LP stim-
ulates EBNA-2 acidic domain-mediated transcriptional activation. J. Virol.
71:6611–6618.
16. Johannsen, E., E. Koh, G. Mosialos, X. Tong, E. Kieff, and S. R. Grossman.
1995. Epstein-Barr virus nuclear protein 2 transactivation of the latent mem-
brane protein 1 promoter is mediated by J
 and PU.1. J. Virol. 69:253–262.
17. Kaiser, C., G. Laux, D. Eick, N. Jochner, G. W. Bornkamm, and B. Kempkes.
1999. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus
nuclear antigen 2. J. Virol. 73:4481–4484.
18. Kato, K., Y. Kawaguchi, M. Tanaka, M. Igarashi, A. Yokoyama, G. Matsuda,
M. Kanamori, K. Nakajima, Y. Nishimura, M. Shimojima, H. T. T. Phung,
E. Takahashi, and K. Hirai. 2001. Epstein-Barr virus-encoded protein kinase
BGLF4 mediates hyperphosphorylation of cellular elongation factor 1 (EF-
1): EF-1 is universally modified by conserved protein kinases of herpesvi-
ruses in mammalian cells. J. Gen. Virol. 82:1457–1463.
19. Kato, K., A. Yokoyama, Y. Tohya, H. Akashi, Y. Nishiyama, and Y. Kawagu-
chi. 2003. Identification of protein kinases responsible for phosphorylation of
Epstein-Barr virus nuclear antigen leader protein at serine-35, which regu-
lates its coactivator function. J. Gen. Virol. 84:3381–3392.
20. Kawaguchi, Y., and K. Kato. 2003. Protein kinases conserved in herpesvi-
ruses potentially share a function mimicking the cellular protein kinase cdc2.
Rev. Med. Virol. 13:331–340.
21. Kawaguchi, Y., K. Kato, M. Tanaka, M. Kanamori, Y. Nishiyama, and Y.
Yamanashi. 2003. Conserved protein kinases encoded by Herpesviruses and
cellular protein kinase cdc2 target the same phosphorylation site in eukary-
otic elongation factor 1. J. Virol. 77:2359–2368.
22. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent
membrane protein 1 is essential for B-lymphocyte growth transformation.
Proc. Natl. Acad. Sci. USA. 90:9150–9154.
23. Kudoh, A., M. Fujita, T. Kiyono, K. Kuzushima, Y. Sugaya, S. Izuta, Y.
Nishiyama, and T. Tsurumi. 2003. Reactivation of lytic replication from B
cells latently infected with Epstein-Barr virus occurs with high S-phase cy-
5884 NOTES J. VIROL.
clin-dependent kinase activity while inhibiting cellular DNA replication.
J. Virol. 77:851–861.
24. Kwiatkowski, B., S. Y. J. Chen, and W. H. Schubach. 2004. CKII site in
Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is
important for growth transformation. J. Virol. 78:6067–6072.
25. Lee, J.-S., K. M. Collins, A. L. Brown, C.-H. Lee, and J. H. Chung. 2000.
hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage
response. Nature 404:201–204.
26. Lee, S. Y., M. R. Wenk, Y. Kim, A. C. Nairn, and P. De Camilli. 2004.
Regulation of synaptojanin 1 by cyclin-dependent kinase 5 at synapses. Proc.
Natl. Acad. Sci. USA. 101:546–551.
27. Ling, P. D., J. J. Hsieh, I. K. Ruf, D. R. Rawlins, and S. D. Hayward. 1994.
EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cel-
lular CD23 promoter utilizes a common targeting intermediate, CBF1. J. Vi-
rol. 68:5375–5383.
28. Lowe, M., C. Rabouille, N. Nakamura, R. Watson, M. Jackman, E. Jamsa, D.
Rahman, D. J. C. Pappin, and G. Warren. 1998. Cdc2 kinase directly phos-
phorylates the cis-Golgi matrix protein GM130 and is required for Golgi
fragmentation in mitosis. Cell 94:783–793.
29. Marschall, M., M. Stein-Gerlach, M. Freitag, R. Kupfer, M. van den Bo-
gaard, and T. Stamminger. 2002. Direct targeting of human cytomegalovirus
protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral
therapy. J. Gen. Virol. 83:1013–1023.
30. McGeoch, D. J., and A. J. Davison. 1986. Alphaherpesviruses possess a gene
homologous to the protein kinase gene family of eukaryotes and retroviruses.
Nucleic Acids Res. 14:1765–1777.
31. Meitinger, C., L. J. Strobl, G. Marschall, G. W. Bornkamm, and U. Zimber-
Strobl. 1994. Crucial sequences within the Epstein-Barr virus TP1 promoter
for EBNA2-mediated transactivation and interaction of EBNA2 with its
responsive element. J. Virol. 68:7497–7506.
32. Ning, S., A. M. Hahn, L. E. Huye, and J. S. Pagano. 2003. Interferon
regulatory factor 7 regulates expression of Epstein-Barr virus latent mem-
brane protein 1: a regulatory circuit. J. Virol. 77:9359–9368.
33. Nitsche, F., A. Bell, and A. Rickinson. 1997. Epstein-Barr virus leader pro-
tein enhances EBNA-2-mediated transactivation of latent membrane protein
1 expression: a role for the W1W2 repeat domain. J. Virol. 71:6619–6628.
34. OReilly, D. R., L. K. Miller, and V. A. Luckow. 1992. Baculovirus expression
vectors: a laboratory manual. W. H. Freeman and Company, New York,
N.Y.
35. Petti, L., C. Sample, and E. Kieff. 1989. Subnuclear localization and phos-
phorylation of Epstein-Barr virus latent infection nuclear proteins. Virology
176:563–574.
36. Prince, S., S. Keating, C. Fielding, P. Brennan, E. Floettmann, and M. Rowe.
2003. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle
induction and progress via different mechanisms. J. Virol. 77:5000–5007.
37. Rayet, B., Y. Fan, and C. Gelinas. 2003. Mutations in the v-Rel transactiva-
tion domain indicate altered phosphorylation and identify a subset of NF-

B-regulated cell death inhibitors important for v-Rel transforming activity.
Mol. Cell. Biol. 23:1520–1533.
38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Expression of cloned
genes in Escherichia coli. In C. Nolan (ed.), Molecular cloning: a laboratory
manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
39. Sauter, M., and N. Mueller-Lantzsch. 1987. Characterization of an Epstein-
Barr virus nuclear antigene 2 variant (EBNA2B) by specific sera. Virus Res.
8:152.
40. Schlee, M., T. Krug, O. Gires, R. Zeidler, W. Hammerschmidt, R. Mailham-
mer, G. Laux, G. Sauer, J. Lovric, and G. W. Bornkamm. 2004. Identification
of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by
proteome analysis: activation of EBNA2 in conditionally immortalized B
cells reflects early events after infection of primary B cells by EBV. J. Virol.
78:3941–3952.
41. Smith, R. F., and T. F. Smith. 1989. Identification of new protein kinase-
related genes in three herpesviruses, herpes simplex virus, varicella-zoster
virus, and Epstein-Barr virus. J. Virol. 63:450–455.
42. Spender, L. C., G. H. Cornish, B. Rowland, B. Kempkes, and P. J. Farrell.
2001. Direct and indirect regulation of cytokine and cell cycle proteins by
EBNA-2 during Epstein-Barr virus infection. J. Virol. 75:3537–3546.
43. Sung, N. S., S. Kenney, D. Gutsch, and J. S. Pagano. 1991. EBNA-2 trans-
activates a lymphoid-specific enhancer in the Bam H1 C promoter of Ep-
stein-Barr virus. J. Virol. 65:2164–2169.
44. Wang, F., C. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A.
Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein
(LMP-1) and nuclear protein 2 and 3C are effectors of phenotypic changes
in B lymphocytes: EBNA-2 and LMP-1 cooperatively induce CD23. J. Virol.
64:2309–2318.
45. Wang, F., S. F. Tsang, M. G. Kurilla, J. I. Cohen, and E. Kieff. 1990.
Epstein-Bar virus nuclear antigen 2 transactivates latent membrane protein
LMP-1. J. Virol. 64:3407–3416.
46. Yokoyama, A., M. Tanaka, G. Matsuda, K. Kato, M. Kanamori, H. Ka-
wasaki, H. Hirano, I. Kitabayashi, M. Ohki, K. Hirai, and Y. Kawaguchi.
2001. Identification of major phosphorylation sites of Epstein-Barr virus
nuclear antigen leader protein (EBNA-LP): ability of EBNA-LP to induce
latent membrane protein 1 cooperatively with EBNA-2 is regulated by phos-
phorylation. J. Virol. 75:5119–5128.
47. Yue, W., M. G. Davenport, J. Shackelford, and J. S. Pagano. 2004. Mitosis-
specific hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 sup-
presses its function. J. Virol. 78:3542–3552.
VOL. 79, 2005 NOTES 5885
